50th anniversary of aldosterone

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 6, 2003, Pages 2364-2372

  Williams, Jonathan S ^a   Williams, Gordon H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMPHENONE; ENALAPRIL; EPLERENONE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADRENAL CORTEX FUNCTION; ALDOSTERONE RELEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIETARY INTAKE; DRUG EFFECT; ESSENTIAL HYPERTENSION; GENETIC ANALYSIS; GENOMICS; HEART FAILURE; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; HYPOKALEMIA; KIDNEY DISTAL TUBULE; LOW DRUG DOSE; MOLECULAR BIOLOGY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT; TREATMENT OUTCOME;

EID: 0038482199     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030490     Document Type: Review

References (91)

1. Castiglioni A 1941 A history of medicine. New York: Alfred A. Knopf; 428
2. Addison T 1855 On the constitutional local effects of disease of the suprarenal capsules. London: P. Highley
3. Kuizinga MH, Cartland GF 1939 Fractionation studies on adrenal cortical extract with notes on the distribution of biological activity among the crystalline and amorphous fractions. Endocrinology 24:526-535
4. Deane HW, Shaw JH, Greep RO 1948 The effect of altered sodium or potassium intake on the width and cytochemistry of the zona glomerulosa of the rat's adrenal cortex. Endocrinology 43:133-153
5. Simpson SA, Tait JF, Wettstein A, Neher R, von Euw J, Reichstein T 1953 Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia 9:333-335
6. Simpson SA, Tait JF, Wettstein A. Neher R. Euw JV, Schindler O, Reichstein T 1954 Aldosteronisolierung und Eigenschaffen über Bestandteile de Nebennierenrinde und verwandte Stoffe. Helv Chim Acta 37:1163-1200
7. Kliman B, Peterson RE 1958 Isotope derivative assay of aldosterone in biological extracts. Fed Proc 17:255 (Abstract)
8. Conn JW 1955 Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 45:3-17
9. Giroud CJP, Stachenko J, Venning EH 1956 Secretion of aldosterone by the zona glomerulosa of rat adrenal glands incubated in vitro. Proc Soc Exp Biol Med 92:154-158
10. Ganong WF, Mulrow PJ 1962 Role of the kidney in adrenocortical response to hemorrhage in hypophysectomized dogs. Endocrinology 70:182-188
11. Mulrow PJ 1966 Neural and other mechanisms regulating aldosterone secretion. In: Martini L, Ganong WF, eds. Neuroendocrinology, vol. 1. New York: Academic Press; 407-444
12. Deane HG, Mason GMC 1951 Adrenal cortical changes in rats with various types of experimental hypertension. J Clin Endocrinol 11:193-208
13. Paige IH, Helmer OM 1939 A crystalline pressor substance, angiotonin, resulting from the reaction between renin and renin activator. Proc Cent Soc Clin Invest 12:17
14. Skeggs LT, Marsh WH, Kahn JR, Shumway NP 1954 The existence of two forms of hypertension. J Exp Med 99:275
15. Gross F 1958 Renin und Hipertensin, physiologische oder pathologische Wirkstoffe? Klin Wochenschr 36:693-706
16. Mulrow PJ, Ganong WF 1961 Stimulation of aldosterone secretion by angiotensin II. Yale J Biol Med 33:386-395
17. Giroud CJP, Saffran M, Schally AV, Stachenko J, Vinning EH 1956 Production of aldosterone by rat adrenal glands in vitro. Proc Soc Exp Biol Med 92:855
18. Laragh JH, Stoerk HC 1957 A study of the mechanism of secretion of the sodium-retaining hormone (aldosterone). J Clin Invest 36:383
19. Leaf A, Anderson J, Page LB 1958 Active sodium transport by the isolated toad bladder. J Gen Physiol 41:657
20. Tullner WW, Graff MM 1956 Amphenone inhibition of adrenal corticosterone in the hypophysectomized dog. Endocrinology 58:280
21. Deleted in proof.
22. Crabbe JJ 1961 Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro. J Clin Invest 40:2103
23. Feigelson, P, Feigelson M, Greengard O 1962 Comparison of the mechanisms of hormonal and substrate induction of rat liver tryptophan pyrrolase. Recent Prog Horm Res 18:491
24. Steigler M, Reichstein T 1937 Desoxycorticosterone (21-oxyprogesterone aus 5-3-oxy-atio cholensaure). Helv Chim Acta 20:1164
25. Conn JW 1964 Plasma renin activity in primary aldosteronism. JAMA 190:222-225
26. Duncun Jr LE, Liddle GW, Bartter FC 1956 The effect of changes in body sodium on extracellular fluid volume and aldosterone and sodium excretion by normal and edematous man. J Clin Invest 35:1299
27. Wolff HP, Koczorek KR, Buchborn E 1957 Lancet 2:63
28. Selye H 1946 The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 6:117-230
29. Selye H 1960 Protection by a steroid-spirolactone against certain types of cardiac necrosis. Proc Soc Exp Biol Med 104:212-213
30. Hall CE, Hall O 1965 Hypertension and hypersalimentation. I Aldosterone hypertension. Lab Invest 14:285-294
31. Gerarde HW, Jones M 1953 The effect of cortisone on collagen synthesis in vitro. J Biol Chem 201:553-560
32. Mayes D, Furuyama D, Kem DC, Nugent CA 1970 A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab 30:682-685
33. Haning R, Tait SAS, Tait JF 1970 In vitro effects of ACTH, angiotensins, serotonin, and potassium on steroid output and conversion of corticosterone to aldosterone by isolated adrenal cells. Endocrinology 87:1147-1167
34. Deleted in proof
35. Hollenberg NK, Chenitz WR, Adams DF, Williams GH 1974 Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Inves 54:34-42
36. Boyd GW, Adamson AR, Arnold M, James VH, Peart WS 1972 The role of angiotensin II in the control of aldosterone in man. Clin Sci 42:91-104
37. Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JI 1974 Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res 34:69-77
38. Muller AF, Riondel AM, Manning EL 1956 Effect of corticotrophin on secretion of aldosterone. Lancet 2:1021-1024
39. Williams GH, Dluhy RG 1972 Aldosterone biosynthesis. Interrelationship of regulatory factors. Am J Med 53:595-605
40. Aguilera G, Catt KJ 1978 Regulation of aldosterone secretion by the renin-angiotensin system during sodium depletion in rats. Proc Natl Acad Sci USA 75:4057-4061
41. Williams GH, Hollenberg NK, Braley LM 1976 Influence of sodium intake on vascular and adrenal angiotensin II receptors. Endocrinology 98:1343
42. Braley LM, Menachery AI, Rystedt L, Williams GH 1989 Sodium-mediated modulation of aldosterone secretion: impact of converting enzyme inhibition on rat glomerulosa cell response to angiotensin II. Endocrinology 125:1310-1315
43. Mortensen RM, Williams GH 1995 Aldosterone action. In: DeGroot LJ, ed. Endocrinology, 3rd ed. Philadelphia: WB Saunders Co.; 1668-1676
44. Garren LD, Gill GN, Masui H, Walton GM 1971 On the mechanism of action of ACTH. Recent Prog Horm Res 27:433-478
45. Sala GB, Hayashi K, Catt KJ, Dufau ML 1979 Adrenocorticotropin action in isolated adrenal cells. The intermediate role of cyclic AMP in stimulation of corticosterone synthesis. J Biol Chem 254:3861-3865
46. Kojima I, Kojima K, Rasmussen H 1985 Intracellular calcium and adenosine 3′,5′-cyclic monophosphate as mediators of potassium-induced aldosterone secretion. Biochem J 228:69-76
47. Hyatt PJ, Tait JF, Tait SAS 1986 The mechanism of the effect of K+ on the steroidogenesis of rat zona glomerulosa cells of the adrenal cortex: role of cyclic AMP. Proc R Soc Lond Biol 227:21-42
48. Streeten DHP, Schletter FE, Clift GV, Stevenson CT, Dalakos TG 1969 Studies of the renin-angiotensin-aldosterone system in patients with hypertension and in normal subjects. Am J Med 46:844-861
49. Baer L, Sommers SC, Krakoff LR, Newton MA, Laragh JH 1970 Pseudoprimary aldosteronism: an entity distinct from true primary hyperaldosteronism. Circ Res (Suppl 1) 27:203
50. Williams GH, Braley LM, Underwood RH 1976 The regulation of plasma 18-hydroxy 11-deoxycorticosterone in man. J Clin Invest 58:221-229
51. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK 1983 Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 72:2115-2124
52. Hollenberg NK, Williams GH 1995 Abnormal renal function, sodium-volume homeostasis and renin system behavior in normal-renin essential hypertension: the evolution of the non-modulator concept. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management, ed 2. New York: Raven Press, Ltd.; 1837-1856
53. Redgrave JE, Rabinowe SL, Hollenberg NK, Williams GH 1985 Correction of abnormal renal blood flow response to angiotensin II by converting-enzyme inhibition in essential hypertensives. J Clin Invest 75:1285-1290
54. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK 1992 Non-modulation as an intermediate phenotype in essential hypertension. Hypertension 20:788-796
55. Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinowe S, Williams GH 1986 Abnormal renal sodium handling in essential hypertension: relation to failure of renal and adrenal modulation of responses to Ang II. Am J Med 81:412-418
56. Ferri C, Bellini C, Desideri G, Valenti M, De Mattia G, Santucci A, Hollenberg NK, Williams GH 1999 Relationship between insulin resistance and non-modulating hypertension: linkage of metabolic abnormalities and cardiovascular risk. Diabetes 48:1623-1630
57. Hopkins PN, Hunt SC, Jeunemaitre X, Smith B, Solorio D, Fisher ND, Hollenberg NK, Williams GH 2002 Angiotensin genotype effect on renal and adrenal responses to angiotensin II in essential hypertension. Circulation 105:1921-1927
58. Rousseau G, Baxter JD, Funder JW, Edelman IS, Tomkins GM 1972 Glucocorticoid and mineralocorticoid receptors for aldosterone. J Steroid Biochem 3:219-227
59. Farman NA, Vandewalle A, Bonvalet JP 1982 Aldosterone binding in isolated tubules: 2. An autoradiographic study of concentration dependency in the rabbit nephron. Am J Physiol 242:F69
60. Sheppard K, Funder JW 1987 Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. Am J Physiol 252:E224
61. Stewart PM, Corrie JE, Shackleton CH, Edwards CR 1988 Syndrome of apparent mineralocorticoid excess: A defect in the cortisol-cortisone shuttle. J Clin Invest 82:340-349
62. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR 1987 Mineralocorticoid activity in licorice: 11 beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2:821
63. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM 1987 Cloning of human mineralocorticoid receptor complimentary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
64. Williams GH 1992 Guardian of the gate: receptors, enzymes, and mineralocorticoid function. J Clin Endocrinol Metab 74:961-962
65. Rossier BC 1997 The 1996 Homer Smith Award Lecture. Curn grano salis: the epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol 8:980-992
66. Verrey F 1999 Early aldosterone action: toward filling the gap between transcription and transport. Am J Physiol 277:F319-F327
67. Chen SY, Bhargava A, Mastroberardino L, Meijer OC, Wang J, Buse P, Firestone GL, Verrey F, Pearce D 1999 Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA 96:2514-2519
68. Silvestre J-S, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C 1998 Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 273:4883-4891
69. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY, Takeda R 1995 Production of aldosterone in isolated rat blood vessels. Hypertension 25:170-173
70. Silvestre J-S, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C 1999 Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99:2694-2701
71. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT 1990 Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 67:1355-1364
72. Brilla CG, Weber KT 1992 Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26:671-677
73. Brilla CG, Pick R, Tan LP, Janicki JS, Weber KT 1990 Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 67:1355-1364
74. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT 1998 Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31:451-458
75. Napoli C, DiGregorio F, Leccese M, Abete P, Ambrosio G, Giusti R, Casini A, Ferrara N, DeMatteis C, Sibilio G, Donzelli R, Montemarano A, Mazzo C, Rengo F, Mansi L, Liguori A 1999 Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: the Cross-sectional Primary Aldosteronism and Hear Italian Multicenter Study. J Invest Med 47:212-221
76. Pitt B, Zannad F, Remme WJ 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717
77. Zannad F, Alla F, Dousset B, Perez A, Pitt B, RALES Investigators 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study. Circulation 102:2700-2706
78. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA Kekec BK, Blomme EA, McMahon EG, Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol-Heart and Circ Physiol. 283:H1802-H1810
79. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871-3878
80. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK 2002 Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 39:614-618
81. Farman N, Rafestin-Oblin ME 2001 Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 280:F181-F192
82. Funder JW 1997 Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 48:231-240
83. Wehling M, Eisen C, Christ M 1992 Aldosterone-specific membrane receptors and rapid non-genomic actions of mineralocorticoids. Mol Cell Endocrinol 90:C5-C9
84. Passaquin AC, Lhote P, Ruegg UT 1998 Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 124:1751-1759
85. Doolan CM, Condliffe SB, Harvey BJ 2000 Rapid non-genomic activation of cytosolic cyclic AMP-dependent protein kinase activity and [Ca(2+)](i) by 17-β-estradiol in female rat distal colon. Br J Pharmacol 129:1375-1386
86. Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R 2002 Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 40:130-135
87. Wehling M, Spes CH, Win N, Janson C, Schmidt BMW, Theisen K, Christ M 1998 Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 83:3517-3522
88. Pitt B, Reichek N, Metscher R, Phillips R, Roniker B, Kleiman J, Burns D 2002 Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Am J Hypertens 15:24A (Abstract)
89. Epstein M, Buckalew V, Martinez F, Altamisano J, Roniker B, Kleiman J, Krausse S 2002 Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 15:24A (Abstract)
90. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA 1993 Evidence that primary aldosteronism may not be uncommon: twelve percent incidence among anti-hypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20:296-298
91. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321